A 35-year-old man with persistent asthma (on inhaled beclomethasone 250 μg twice daily) presents with 4 weeks of progressive dyspnea on exertion, nocturnal cough 3 times per week, and morning wheeze despite adherence to his inhaler. Peak expiratory flow (PEF) is 75% of predicted. Spirometry shows FEV₁ 68% of predicted with incomplete reversibility after salbutamol. He denies recent infections, new triggers, or medication changes. What is the most appropriate next step in asthma management?

Explanation

## Asthma Control Assessment and Step-Up Therapy ### Clinical Assessment of Control This patient has **inadequately controlled persistent asthma** despite low-to-moderate dose ICS monotherapy: | Feature | Patient Status | Control Level | |---------|---|---| | Daytime symptoms | Dyspnea on exertion | Not controlled | | Nocturnal symptoms | 3×/week | Not controlled | | FEV₁ | 68% predicted | Reduced | | PEF | 75% predicted | Suboptimal | | Medication adherence | Good | — | **Key Point:** Inadequate control on ICS monotherapy (even at moderate doses) is an indication for **step-up therapy**, not dose escalation of the same agent alone. ### GINA Step-Up Therapy Algorithm ```mermaid flowchart TD A[Persistent asthma on ICS monotherapy]:::outcome --> B{Asthma controlled?}:::decision B -->|Yes| C[Continue current therapy<br/>+ regular review]:::action B -->|No| D{Assess adherence<br/>& technique}:::decision D -->|Poor| E[Optimize adherence<br/>& inhaler technique]:::action D -->|Good| F[Step-up therapy]:::action F --> G{Current step?}:::decision G -->|Step 2: Low ICS| H[Add LABA<br/>ICS + LABA combination]:::action G -->|Step 3: ICS + LABA| I[Increase ICS dose<br/>or add LTRA/LAMA]:::action H --> J[Reassess in 4 weeks]:::action I --> J ``` ### Why This Patient Requires Step-Up **High-Yield:** The patient is on **Step 2 therapy** (low-dose ICS monotherapy: beclomethasone 250 μg BD is equivalent to ~200 μg fluticasone BD). Inadequate control indicates need for **Step 3: ICS + LABA**. **Rationale for ICS + LABA combination:** 1. **Superior efficacy** — LABA + ICS reduces exacerbations and improves lung function vs. ICS alone or ICS dose escalation [cite:GINA 2023] 2. **Prevents LABA monotherapy** — LABA without ICS increases mortality risk; always use LABA + ICS together 3. **Convenient dosing** — combination inhalers improve adherence 4. **Evidence-based** — GINA and BTS/SIGN recommend ICS + LABA as preferred step-up from ICS monotherapy ### Option Analysis #### Option 1: Increase Beclomethasone + Add LABA This is **partially correct in concept** (adding LABA is right) but **suboptimal in execution**: - Increasing beclomethasone to 500 μg BD is dose escalation without LABA benefit - Separate inhalers reduce adherence - Combination inhaler (Option 1) is preferred #### Option 2: Fluticasone + Salmeterol Combination (CORRECT) - **Fluticasone 250 μg + salmeterol 50 μg BD** is a fixed-dose ICS/LABA combination - Fluticasone 250 μg is equivalent to beclomethasone 500 μg (higher potency) - Salmeterol 50 μg is a standard LABA dose - Single inhaler improves adherence - This is **Step 3 therapy** per GINA guidelines - Reassess control in 4 weeks; if still inadequate, consider increasing ICS dose further or adding LTRA/LAMA **Clinical Pearl:** When stepping up from ICS monotherapy, always add a LABA (not increase ICS dose alone). The combination is more effective than ICS dose escalation. #### Option 3: Allergy Testing & Immunotherapy - Appropriate only if **specific IgE-mediated triggers** are identified - Not first-line for inadequate control on ICS - Would delay necessary step-up therapy - Immunotherapy takes months to show benefit #### Option 4: Bronchoscopy - No indication in this patient - No features suggesting alternative diagnosis (e.g., fixed airway obstruction, vocal cord dysfunction, aspiration) - Spirometry shows reversible airflow obstruction consistent with asthma - Unnecessary investigation ### Mnemonic: GINA Step-Up **"ICS → ICS+LABA → ICS+LABA+LTRA/LAMA → Biologic"** - Step 2: ICS monotherapy - **Step 3: ICS + LABA** ← This patient - Step 4: ICS + LABA + LTRA or LAMA - Step 5: High-dose ICS + LABA ± biologic (omalizumab, mepolizumab, etc.) ### Post-Step-Up Management - Reassess asthma control in **4 weeks** - If controlled, continue and review annually - If still uncontrolled, consider: - Checking adherence and technique again - Increasing ICS dose (Step 4) - Adding LTRA (montelukast) or LAMA (tiotropium) - Investigating for severe asthma phenotypes (eosinophilic, allergic) if FEV₁ remains <60%